January 8, 2010

Seikagaku Corporation
(Securities Code: 4548)

Receipt of Result for the U.S. PMA of Gel-200

Seikagaku Corporation (“Seikagaku”) (head office: Chiyoda-ku, Tokyo) received a letter from the U.S. Food and Drug Administration (FDA) on January 5, 2010 (Japan time) that the U.S. Premarket Approval Application (PMA) of Gel-200, a medical device for knee osteoarthritis, is “Not Approvable”.

Seikagaku is confident that Gel-200 is a useful medical device, and is planning to internally consider the necessary measures to make the application approvable and to continue to discuss with the FDA in order to receive the approval. Seikagaku will release any updates on the progress of this matter from time to time.

Gel-200 is an intra-articular injection which contains cross-linked hyaluronate hydrogel as its main ingredient and which was developed to provide a long-term pain relief with a single injection. PMA was submitted to the FDA in July 2008 and has been under the FDA’s review ever since.

#######